Summary
Definition
History and exam
Key diagnostic factors
- prolonged tonic-clonic seizures with an altered level of consciousness (convulsive SE)
- altered level of consciousness, confusion or change in personality with limited or absent motor findings (non-convulsive SE)
- risk factors
Risk factors
- poor anticonvulsant therapy adherence
- alcohol-use disorder
- stroke
- toxic or metabolic causes
- refractory epilepsy
- processes leading to direct cortical structural damage
- use of restricted or recreational drugs
Diagnostic investigations
1st investigations to order
- glucose
- arterial blood gases
- urea
- creatinine
- liver function tests
- sodium, calcium, and magnesium
- full blood count
- C-reactive protein
- clotting screen
- anticonvulsant drug levels
- chest x-ray
Investigations to consider
- ECG
- CT-head
- lumbar puncture
- toxicology screen
Treatment algorithm
convulsive status epilepticus: in hospital
convulsive status epilepticus: in the community
non-convulsive status epilepticus
Contributors
Expert advisers
Matthew Jones, MD, FRCP
Consultant Neurologist
Manchester Centre for Clinical Neurosciences
Northern Care Alliance
Honorary Senior Lecturer
University of Manchester
Manchester
UK
Biography
MJ is an honorary senior lecturer at the University of Manchester.
Disclosures
MJ is the chair of the Association of British Neurologists Education Committee (unpaid position). MJ is a faculty member of an MRCP revision course. MJ has received honoraria from Eisai for educational talks.
Rachael Power, MBChB, MRCP
Neurology Registrar
Manchester Centre for Clinical Neurosciences
Salford Royal NHS Foundation Trust
UK
Disclosures
RP has been sponsored by Novartis to attend the International Headache Conference.
Acknowledgements
BMJ Best Practice would like to gratefully acknowledge the previous team of expert contributors, whose work is retained in parts of the content:
Ronald P. Lesser, MD
Professor of Neurology and Neurosurgery
Johns Hopkins Medical Institutions
Baltimore
MD
Disclosures: RPL's wife holds shares in Abbott Laboratories, which makes Depakote, a brand formulation of valproate/divalproex. RPL holds shares in Abbvie, Express Scripts, Halgene, Halyard Health, Hospira, Johnson and Johnson (which makes Topamax, a brand formulation of topiramate), Merck and Company, and Pfizer (which makes Dilantin and Cerebyx, brand formulations of phenytoin and fosphenytoin, respectively).
Emily Johnson, MD
Assistant Professor of Neurology
Johns Hopkins Medical Institutions
Baltimore
MD
Disclosures: EJ declares that she has no competing interests.
Peer reviewers
Hannah Cock, MD, FRCP
Professor of Epilepsy and Medical Education
Consultant Neurologist
St George's University Hospitals NHS Foundation Trust
London
UK
Disclosures
HC has received personal fees from Sage Pharmaceuticals Ltd, Eisai Europe Ltd, UCB Pharma Ltd, the European Medicines Agency, the UK Epilepsy Nurse Specialist Association, Bial, and Eisai. She has received non-financial support from Special Products Ltd, the European Academy of Neurology, and the International League Against Epilepsy E-learning Task Force. She has received grants from the US NIH Institute of Neurological Disorders and Stroke. HC also reports other conflicting interests related to Novartis and GW Research Ltd. HC is an author of a number of references cited in this topic.
Differentials
- Non-epileptic (dissociative) seizures
- Delirium
- Coma
More DifferentialsGuidelines
- Epilepsies in children, young people and adults
- Diagnosis and management of epilepsy in adults: a national clinical guideline
More GuidelinesCalculators
Glasgow Coma Scale
More CalculatorsPatient information
Epilepsy: what is it?
Epilepsy: what treatments work?
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer